Exicure Inc (XCUR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.43+1.42%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
Exicure is cutting losses and cash burn. Operating loss improved from $7.59M to $1.64M. Cash burn fell from $3.53M to $1.14M. New COO and milestone achievement show progress.
The company is still losing money and burning cash. CEO and CFO left recently. Sales and profits remain weak. The stock price dropped over 50%.
The market prices in a risky biotech turnaround with ongoing losses. No clear growth or profit targets are priced in. Our view is cautious given management changes and weak cash flow.
Breaks if: cash burn worsens beyond negative $1.14 million next year
Maintain cost discipline to control operating losses and negative cash flow amid clinical development and restructuring.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is focused on advancing clinical programs, but it is currently loss-making and faces high risks, especially with recent management changes.
The market seems to reflect a low fragility tier, indicating that while XCUR is considered expensive, this does not fully account for its weak fundamentals and turbulent management situation. Investors may be assuming some level of future success based on the healthcare sector's overall momentum.
The fundamentals are likely to remain neutral in the near term, as the company continues to manage operating expenses and cash burn while pursuing clinical milestones. However, the lack of revenue and ongoing losses suggest that significant commercial progress is still needed.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as their earnings results could influence XCUR's trajectory. Additionally, the ability of management to stabilize operations and advance clinical programs will be crucial.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 4 of last 4 quarters. Operating income improved from -$2.39M in 2025-Q3 to -$1.05M in 2026-Q2, and cash from operations improved from -$3.53M to -$0.89M over the same period. Management's focus on expense and cash burn control is reflected in these improving operating losses and cash flow, indicating progress in managing costs amid restructuring.
“Focus on managing operating expenses and cash burn amid restructuring.”
“Committed to controlling operating expenses and cash burn.”
“Continued emphasis on expense management and cash flow control.”
“Ongoing efforts to manage operating expenses and cash burn.”
Breaks if: additional CEO or CFO departures occur
Breaks if: operating loss worsens beyond negative $1.64 million next year
Maintain cost discipline to control operating losses and negative cash flow amid clinical development and restructuring.
Stated as a priority in 4 of last 4 quarters. Operating income improved from -$2.39M in 2025-Q3 to -$1.05M in 2026-Q2, and cash from operations improved from -$3.53M to -$0.89M over the same period. Management's focus on expense and cash burn control is reflected in these improving operating losses and cash flow, indicating progress in managing costs amid restructuring.
“Focus on managing operating expenses and cash burn amid restructuring.”
“Committed to controlling operating expenses and cash burn.”
“Continued emphasis on expense management and cash flow control.”
“Ongoing efforts to manage operating expenses and cash burn.”
Over the next 1 to 3 years, XCUR's prospects depend on external sector performance and internal management execution. Not investment advice.